• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    CGS Transforms Workplace Training with Cicero, a New AI-Driven, Customizable Roleplay Platform

    3/10/25 7:00:00 AM ET
    $MDT
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care
    Get the next $MDT alert in real time by email

    NEW YORK, March 10, 2025 (GLOBE NEWSWIRE) -- CGS Immersive™, the leader in enterprise learning that is modernizing training and development with AI and XR technologies, today introduced Cicero™, a hyper realistic roleplay application for upskilling workforces. Using AI-powered interactions, Cicero facilitates immersive roleplay using lifelike personas and real-time feedback in scenarios so realistic, it helps trainees to master the unexpected things that happen in real-life interactions with customers and other business contacts.

    The need for innovative learning and development programs has never been more urgent as technology is disrupting the regular course of business and workplace interactions. In fact, the gap in employee soft skills costs the U.S. economy $160B annually1. Cicero helps employees develop skills and enhances job performance by unlocking the power of roleplay, practice, personalized guidance, and feedback.

    "The increasing demand for immersive training solutions highlights the importance of platforms that blend AI and extended reality (XR) to address critical workforce skill gaps. Roleplay solutions that can enhance human skills are fundamental, making them essential for workforce transformation and future-readiness," said Gina Smith, Ph.D., Research Director, IDC.

    Medtronic (NYSE:MDT), a global leader in healthcare technology, is among the first to deploy Cicero to upskill its teams in sales enablement and surgical education. "The Cicero application is a significant leap forward in surgical training technology," said Colleen Tully, Senior Program Manager, Learning Technology Innovation at Medtronic. "Cicero's XR-enabled roleplays will revolutionize our sales enablement, surgical education and other medical training. We're excited about Cicero helping us improve healthcare delivery."

    "CGS companies help clients thrive in dynamic, competitive environments by ensuring excellence in the execution of their business fundamentals," said Phil Friedman, President & CEO, Computer Generated Solutions, Inc. "Our latest innovation, Cicero reflects our long-held commitment to developing technologies that solve the most urgent opportunities, like upskilling employees for the future of work."

    Cicero empowers leaders to prepare their teams for any challenge — whether it's boosting sales, improving customer satisfaction, or navigating complex scenarios. In minutes, team leaders and L&D professionals can easily create tailored roleplay simulations that mimic real life business situations. This can span helping sales reps tasked with selling pharmaceuticals to skeptical physicians to training flight attendants in maintaining calm and etiquette with unruly passengers.

    Cicero offers unscripted, fully customizable scenarios to upskill employees using hyper-realistic XR-powered workplace settings that can be used across any number of industries. Custom simulations can be created in minutes by setting the scene, using existing in-house materials, and selecting personas modeled on the five common personality traits: extroversion, agreeableness, openness, conscientiousness, and neuroticism. Other key benefits include:

    • Rehearse complex tasks: reduce risks in a controlled environment;
    • Practice safely: gain real-time feedback and develop important skills without the pressure of a high stakes setting;
    • Always-on AI coach: deliver personalized guidance 24/7 to help employees upskill faster;
    • Ensure continuous improvement: track individual and team progress, harnessing data driven insights that empower the identification of improvement areas;
    • Multilingual, scalable, and cost-effective: Cicero is designed to grow with organizations, even at global scale and across different languages and cultures; and
    • Accurate and accountable: Cicero facilitates accountability through contextual learning and reconciliation records.

    "Traditional workplace training is often generic, costly, and lacking in the real-world context employees need to succeed," said Doug Stephen, President, Enterprise Learning Division, CGS. "With Cicero's hyper-realistic scenarios, businesses can immerse their teams in dynamic, unscripted roleplay simulations for a limitless number of real-world circumstances. The engagement and feedback created with Cicero drives measurable performance improvements and ROI. What normally took teams weeks to develop can now be produced in minutes."

    About CGS Immersive

    CGS Immersive®, Inc., a CGS company, is an innovation lab and training transformation engine dedicated to pioneering leading-edge Extended Reality (XR) training solutions for businesses worldwide. With a focus on leveraging AI and XR technologies, CGS Immersive is modernizing training programs and delivering immersive experiences tailored to meet the evolving needs of organizations across diverse industries. Contact us for more information, and follow CGS Immersive and Cicero on LinkedIn.

    About CGS

    For more than 40 years, CGS has enabled global enterprises, regional companies, and government agencies to drive breakthrough performance through business applications, enterprise learning and outsourcing services. CGS is wholly focused on creating comprehensive solutions that meet clients' complex, multi-dimensional needs, and support clients' most fundamental business activities. Headquartered in New York City, CGS has offices across North America, South America, Europe, the Middle East, and Asia. For more information, please visit www.cgsinc.com and follow us on LinkedIn.

    1 Source: World Economic Forum



    Media Contact
    Alan Marcus
    [email protected]
    Get the next $MDT alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $MDT

    DatePrice TargetRatingAnalyst
    3/4/2025$92.00 → $107.00Neutral → Buy
    Citigroup
    10/10/2024$98.00 → $105.00Sector Perform → Outperform
    RBC Capital Mkts
    8/21/2024$92.00 → $94.00Perform
    Oppenheimer
    8/15/2024$76.00 → $90.00Sell → Neutral
    UBS
    8/14/2024$100.00 → $85.00Buy → Hold
    Stifel
    5/30/2024$83.00Sell
    Goldman
    7/19/2023$90.00Neutral
    Robert W. Baird
    6/30/2023$106.00Buy
    CL King
    More analyst ratings

    $MDT
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by Medtronic plc. (Amendment)

      SC 13G/A - Medtronic plc (0001613103) (Subject)

      2/13/24 5:09:43 PM ET
      $MDT
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • SEC Form SC 13G/A filed by Medtronic plc. (Amendment)

      SC 13G/A - Medtronic plc (0001613103) (Subject)

      2/12/24 1:59:55 PM ET
      $MDT
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • SEC Form SC 13G/A filed by Medtronic plc. (Amendment)

      SC 13G/A - Medtronic plc (0001613103) (Subject)

      2/15/23 3:34:14 PM ET
      $MDT
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $MDT
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Accounting Officer Blomquist Denise L. gifted 310 units of Ordinary Shares, decreasing direct ownership by 3% to 10,143 units (SEC Form 4)

      4 - Medtronic plc (0001613103) (Issuer)

      6/4/25 4:30:34 PM ET
      $MDT
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • New insider Kiil Harry Skip claimed ownership of 33,442 units of Ordinary Shares (SEC Form 3)

      3 - Medtronic plc (0001613103) (Issuer)

      6/4/25 4:29:12 PM ET
      $MDT
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • SVP, Chief HR Officer Walter Matthew R. covered exercise/tax liability with 34 units of Ordinary Shares, decreasing direct ownership by 0.13% to 26,054 units (SEC Form 4)

      4 - Medtronic plc (0001613103) (Issuer)

      5/5/25 4:10:23 PM ET
      $MDT
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $MDT
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Medtronic upgraded by Citigroup with a new price target

      Citigroup upgraded Medtronic from Neutral to Buy and set a new price target of $107.00 from $92.00 previously

      3/4/25 7:37:34 AM ET
      $MDT
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Medtronic upgraded by RBC Capital Mkts with a new price target

      RBC Capital Mkts upgraded Medtronic from Sector Perform to Outperform and set a new price target of $105.00 from $98.00 previously

      10/10/24 7:57:15 AM ET
      $MDT
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Oppenheimer reiterated coverage on Medtronic with a new price target

      Oppenheimer reiterated coverage of Medtronic with a rating of Perform and set a new price target of $94.00 from $92.00 previously

      8/21/24 7:55:37 AM ET
      $MDT
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $MDT
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • AI in Healthcare Just Crossed a Tipping Point. Investors Are Watching These Names

      Equity Insider News Commentary Issued on behalf of Avant Technologies Inc. VANCOUVER, BC, June 4, 2025 /PRNewswire/ -- Equity Insider News Commentary – Generative AI is transforming healthcare faster than almost any other sector, according to a new McKinsey report. In a March survey of senior leaders across payers, providers, and healthcare services groups, 85% said they're actively using or exploring the technology. McKinsey's Global Institute estimates Gen AI could unlock $60–110 billion in annual value across pharma and medical products alone. With more AI pilot programs running than ever before, the tech world is racing to meet demand — including new efforts from Avant Technologies, Inc.

      6/4/25 2:36:00 PM ET
      $BFLY
      $MDT
      $ORCL
      $RXRX
      Medical Electronics
      Health Care
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Computer Software: Prepackaged Software
    • Medtronic chairman and CEO Geoff Martha to speak at Bernstein's Strategic Decisions Conference

      GALWAY, Ireland, May 23, 2025 /PRNewswire/ -- Medtronic plc (NYSE:MDT), a global leader in healthcare technology, today announced it will participate in Bernstein's 41st Strategic Decisions Conference on Thursday, May 29, 2025. Geoff Martha, Medtronic chairman and chief executive officer, will make a formal presentation beginning at 11:00 a.m. EDT (10:00 a.m. CDT). Immediately following the presentation, Martha will be joined by Thierry Piéton, Medtronic executive vice president and chief financial officer, to answer questions about the company. A live webcast of the presentation and Q&A session will be available on May 29, 2025, by clicking on the Events link at http://investorrelations.med

      5/23/25 4:59:00 PM ET
      $MDT
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Medtronic reports strong finish to its fiscal year with its fourth quarter financial results; announces dividend increase

      Building momentum in key franchises including Pulsed Field Ablation, TAVR, Cardiac Rhythm Management, Diabetes, Spine, and Neuromodulation GALWAY, Ireland, May 21, 2025 /PRNewswire/ -- Medtronic plc (NYSE:MDT), a global leader in healthcare technology, today announced financial results for its fourth quarter (Q4) and fiscal year 2025 (FY25), which ended April 25, 2025. Q4 Key Highlights Q4 revenue of $8.9 billion increased 3.9% as reported and 5.4% organicQ4 GAAP diluted EPS of $0.82 increased 67%; non-GAAP diluted EPS of $1.62 increased 11%Q4 operating margin increased 380 basis points; Q4 non-GAAP operating margin increased 90 basis pointsQ4 operating pro

      5/21/25 6:45:00 AM ET
      $MDT
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $MDT
    Leadership Updates

    Live Leadership Updates

    See more
    • Orchestra BioMed Reports Full Year 2024 Financial Results and Provides a Fourth Quarter Business Update

      NEW HOPE, Pa., March 31, 2025 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (NASDAQ:OBIO, "Orchestra BioMed" or the "Company")), a biomedical innovation company accelerating high-impact technologies to patients through risk-reward sharing partnerships, today reported its full year 2024 financial results and provided a fourth quarter business update. "We remain highly focused on execution of the BACKBEAT global pivotal study, which we believe has the potential to deliver landmark results that can establish AVIM therapy as a new standard of care for the treatment of uncontrolled hypertension in patients already indicated for a pacemaker. We also believe it can lay the foundation for

      3/31/25 4:21:30 PM ET
      $MDT
      $OBIO
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
      Medicinal Chemicals and Botanical Products
    • Orchestra BioMed Announces Appointment of Former Medtronic SVP of Corporate Development Christopher Cleary to Board of Directors

      Medical device industry veteran brings over three decades of expertise in M&A, as well as structured research and development ("R&D") collaborations aligned with Orchestra BioMed's partnership-enabled business model Mr. Cleary previously served as Senior Vice President ("SVP") of Corporate Development at Medtronic plc (NYSE:MDT) ("Medtronic"), where he played a key role in establishing the strategic collaboration between Orchestra BioMed and Medtronic for atrioventricular interval modulation ("AVIM") therapy in hypertension with increased cardiovascular riskEric A. Rose, M.D. to transition from Board Member to Board Member Emeritus and Strategic Advisor, continuing to provide invaluable expe

      2/5/25 8:00:00 AM ET
      $MDT
      $OBIO
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
      Medicinal Chemicals and Botanical Products
    • Inogen Announces Appointment of Mira Kirti Sahney to Board of Directors and Retirement of Board Member Tom West

      Inogen, Inc. (Nasdaq: INGN), a medical technology company offering innovative respiratory products for use in the homecare setting, today announced the appointment of Mira Kirti Sahney to Inogen's Board of Directors, effective January 31, 2025. The company also announced that Tom West, who has served as a director since April 2023, retired as a member of the Board of Directors, effective January 30, 2025. "We are thrilled to welcome Mira Sahney to the Inogen Board. Mira brings considerable management, technical, and operational experience in the medical device field to Inogen," said Elizabeth Mora, Chairperson of the Board. "Mira's appointment will further strengthen Inogen's Board with a

      2/3/25 4:00:00 PM ET
      $INGN
      $MDT
      $MYO
      Industrial Specialties
      Health Care
      Biotechnology: Electromedical & Electrotherapeutic Apparatus

    $MDT
    Financials

    Live finance-specific insights

    See more

    $MDT
    SEC Filings

    See more
    • Medtronic announces cash dividend for fourth quarter of fiscal year 2025

      GALWAY, Ireland, March 6, 2025 /PRNewswire/ -- The board of directors of Medtronic plc (NYSE:MDT) on Thursday, March 6, 2025, approved the company's cash dividend for the fourth quarter of fiscal year 2025 of $0.70 per ordinary share. This quarterly declaration is consistent with the dividend increase announcement made by the company in May 2024. Medtronic is a constituent of the S&P 500 Dividend Aristocrats index, having increased its annual dividend payment for the past 47 consecutive years. The dividend is payable on April 11, 2025, to shareholders of record at the close of business on March 28, 2025. About MedtronicBold thinking. Bolder actions. We are Medtronic. Medtronic plc, headquart

      3/6/25 4:30:00 PM ET
      $MDT
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Medtronic reports third quarter fiscal 2025 financial results

      Delivering durable revenue growth with strong earnings power; strength in Pulsed Field Ablation, Pacing, Structural Heart, Diabetes, and Neuromodulation GALWAY, Ireland, Feb. 18, 2025 /PRNewswire/ -- Medtronic plc (NYSE:MDT) today announced financial results for its third quarter (Q3) of fiscal year 2025 (FY25), which ended January 24, 2025. Key Highlights Revenue of $8.3 billion increased 2.5% as reported and 4.1% organicGAAP diluted EPS of $1.01 increased 2%; non-GAAP diluted EPS of $1.39 increased 7%Company reiterates full year revenue and EPS guidanceCardiac Ablation Solutions revenue increased low-20s on strength of pulsed field ablation (PFA) productsU.S. Centers for Medicare and Medic

      2/18/25 6:45:00 AM ET
      $MDT
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Medtronic announces cash dividend for third quarter of fiscal year 2025

      GALWAY, Ireland, Dec. 5, 2024 /PRNewswire/ -- The board of directors of Medtronic plc (NYSE:MDT) on Thursday, December 5, 2024, approved the company's cash dividend for the third quarter of fiscal year 2025 of $0.70 per ordinary share. This quarterly declaration is consistent with the dividend increase announcement made by the company in May 2024. Medtronic is a constituent of the S&P 500 Dividend Aristocrats index, having increased its annual dividend payment for the past 47 consecutive years. The dividend is payable on January 10, 2025, to shareholders of record at the close of business on December 27, 2024. About MedtronicBold thinking. Bolder actions. We are Medtronic. Medtronic plc, hea

      12/5/24 4:30:00 PM ET
      $MDT
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • SEC Form SD filed by Medtronic plc.

      SD - Medtronic plc (0001613103) (Filer)

      5/28/25 5:30:45 PM ET
      $MDT
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Medtronic plc. filed SEC Form 8-K: Results of Operations and Financial Condition, Leadership Update, Other Events, Financial Statements and Exhibits

      8-K - Medtronic plc (0001613103) (Filer)

      5/21/25 6:47:23 AM ET
      $MDT
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Medtronic plc. filed SEC Form 8-K: Leadership Update

      8-K - Medtronic plc (0001613103) (Filer)

      3/17/25 4:30:48 PM ET
      $MDT
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care